KANAPH Therapeutics
Latest round
- Series C
Last raised
- Nov 2024
Total raised
- $40M
Investors
- 12
About KANAPH Therapeutics
Based in Seoul, South Korea, and founded in 2019, KANAPH Therapeutics Inc. focuses on developing innovative biotechnology solutions that target chronic diseases, enhancing treatment outcomes through advanced therapeutic applications. KANAPH Therapeutics Inc. is dedicated to advancing the biotechnology sector by developing targeted therapies. The founder's history is not publicly detailed, nor are any prior ventures indicated. The company has not been reported as a subsidiary or a result of a merger or carve-out. KANAPH Therapeutics Inc. specializes in developing innovative therapeutic solutions aimed at addressing significant health challenges. The company focuses on advancing research in biotechnology, particularly in developing targeted therapies that leverage proprietary technology platforms. Their core product offerings enhance the quality of life for patients suffering from chronic and complex diseases, specifically improving treatment outcomes in oncology and autoimmune disorders.'s products are marketed to hospitals, clinics, and healthcare providers primarily in North America and Europe. KANAPH Therapeutics Inc. generates revenue through strategic partnerships and collaborations within the healthcare sector, particularly with pharmaceutical companies and research institutions. Business transactions typically occur through licensing agreements and joint ventures, allowing for the co-development of their therapeutic products. The company’s flagship offerings are integrated into clinical settings where they are distributed directly to healthcare professionals and institutions. Pricing models for these products are structured around value-based agreements, reflecting the efficacy and impact of their therapies on patient outcomes. KANAPH Therapeutics Inc. is focusing on launching new products that aim to address chronic diseases, although specific release dates have not been disclosed. The company is also planning to expand its presence in additional markets, specifically targeting new regions in North America and Europe by the end of 2025. In March 2026, KANAPH Therapeutics Inc.
Who invested in KANAPH Therapeutics
12 investors across 3 rounds
See all investors in KANAPH Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about KANAPH Therapeutics
Who invested in KANAPH Therapeutics?
KANAPH Therapeutics has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has KANAPH Therapeutics raised?
KANAPH Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did KANAPH Therapeutics last raise money?
KANAPH Therapeutics's most recent round on record is a Series C, in Nov 2024.
What does KANAPH Therapeutics do?
Based in Seoul, South Korea, and founded in 2019, KANAPH Therapeutics Inc.
Where is KANAPH Therapeutics headquartered?
KANAPH Therapeutics is headquartered in Seoul, South Korea.
Which VCs invest in companies like KANAPH Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at KANAPH Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like KANAPH Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.